查詢結果分析
來源資料
相關文獻
- Hepatitis C Virus Genotypes: Clinical Relevance and Therapeutic Implications
- 慢性B型肝炎合併慢性C型肝炎治療之新契機
- C型肝炎
- Assessment of Factors Correlated with Ribavirin Dose Reduction Due to Hemolytic Anemia during Treatment in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin Combination Therapy
- 慢性C型肝炎患者接受抗病毒藥物治療失敗之機轉及因應措施
- 慢性C型肝炎標準照顧在臨床上的療效:南臺灣醫學中心某醫師的經驗
- 慢性C型肝炎治療的新時代
- Falsely Low Hemoglobin A1c Values in Diabetic Patients Receiving Peginterferon-alpha and Ribavirin for Chronic Hepatitis C
- Efficacy of Peginterferon Alfa Plus Ribavirin Treatment for Chronic Hepatitis C Virus Infection in Cirrhotic Patients
- 合併感染C型肝炎及人類免疫不全病毒患者之評估與治療要點
頁籤選單縮合
| 題 名 | Hepatitis C Virus Genotypes: Clinical Relevance and Therapeutic Implications=C型肝炎病毒基因型:臨床意義及治療之相關性 |
|---|---|
| 作 者 | 李全謨; 洪肇宏; 盧勝男; 張簡吉幸; | 書刊名 | 長庚醫學 |
| 卷 期 | 31:1 2008.01-02[民97.01-02] |
| 頁 次 | 頁16-25 |
| 分類號 | 415.5332 |
| 關鍵詞 | C型肝炎病毒基因型; 臨床意義; 治療相關性; 干擾素; 雷巴威林; 宿主因子; Hepatitis C virus genotype; Clinical relevance; Therapeutic implication; Interferon; Ribavirin; Host factor; |
| 語 文 | 英文(English) |
| 英文摘要 | The incidence of hepatitis C virus (HCV) -related hepatocellular carcinoma (HCC) has been increasing in several countries including Taiwan. There are six main genotypes, each of which contains closely related subtypes. Molecular epidemiological studies have shown marked differences in the genotype distribution by geographical region and between patient groups. HCV genotype 1 may play a role in the development of HCC, although some studies have argued against this. A sustained virological response secondary to interferon monotherapy or interferon/ribavirin combination therapy may reduce the risk of HCC and improve survival in chronic hepatitis C patients. The HCV genotypes are associated with therapeutic response. Rapid virological response is also a predictor of therapeutic response. Although viral characteristics have consistently been shown to be important predictors of treatment response, identification of additional host immune and genetic factors involved in determining the outcome of antiviral therapy is necessary. Newly developed bio-techniques (microarray, proteomes, bioinformatics), drugs, and treatment strategies may elucidate the pathogenesis and improve the therapeutic response in HCV infection. |
本系統中英文摘要資訊取自各篇刊載內容。